Perimenopause Treatment Options, Ranked by Evidence

Quick answer: For hot flashes and night sweats, hormone therapy is the most effective treatment there is. For women who can't take it or don't want it, several non-hormonal options carry the highest grade of evidence — two of them not drugs at all.

Every option below carries an evidence level, because that is the piece almost always missing. The guidance this page draws on grades recommendations on a three-point scale: Level I is good and consistent scientific evidence, Level II is limited or inconsistent, Level III is consensus and expert opinion (The Menopause Society, 2023). For scale: hot flashes and night sweats — vasomotor symptoms — occur in up to 80% of menopausal women, last a mean of 7 to 9 years, and in one in three women last over 10 years. Nothing here is prescriptive; doses and suitability are decisions for a clinician who knows your history.

What works best for perimenopause symptoms

Hormone therapy remains the most effective treatment for vasomotor symptoms and for genitourinary syndrome of menopause, and it has been shown to prevent bone loss and fracture. That is the conclusion of the 2022 hormone therapy position statement of The Menopause Society, and the 2023 nonhormone statement restates it (The Menopause Society, 2022).

The risk-benefit picture depends heavily on when treatment starts. For women under 60 or within 10 years of menopause onset who have no contraindications, the 2022 statement found the benefit-risk ratio favourable for treating bothersome vasomotor symptoms and preventing bone loss. For women beginning hormone therapy more than 10 years from menopause onset, or after age 60, it found the ratio appears less favourable, because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia.

That timing distinction is why the perimenopausal reader sits differently from the postmenopausal one. If you are still having periods, you are inside the window the statement describes as favourable — which does not mean hormone therapy is right for you, since contraindications and personal history decide that. It does mean the risk framing many women absorbed years ago came from a largely older trial population: the 2022 statement notes that the Women's Health Initiative had limited enrolment of women under 60 or fewer than 10 years from menopause onset — the group it calls the one for whom hormone therapy is currently primarily indicated.

None of which is a blanket endorsement. Risks differ by type, dose, duration, route, timing and whether a progestogen is used, and the statement calls for treatment to be individualised, with periodic reassessment.

Hormone therapy during perimenopause specifically

Most writing about hormone therapy is really about postmenopause, and it skips what makes perimenopause different: your cycles are still happening, and pregnancy is still possible. The Office on Women's Health states you can still get pregnant during perimenopause even if you miss your period for a month or a few months (OWH), and the National Institute on Aging advises continuing birth control for at least a full 12 months after the last period (NIA). Symptom control and contraception are one conversation here, not two.

That is also why the options raised at a perimenopause appointment are broader. Cleveland Clinic lists antidepressants, birth control pills, hormone therapy, gabapentin, oxybutynin, a hormonal IUD for abnormal or irregular bleeding, and vaginal preparations (Cleveland Clinic). Hormonal contraception appears there because it can address cycle-related bleeding, symptoms and pregnancy prevention at once. We found no verified head-to-head comparison of contraceptive versus menopausal hormone regimens, so this page makes no claim that either is more effective — a question for a clinician rather than a website.

One perimenopause-specific finding is easy to miss. The 2022 statement reports that estrogen therapy's effect on depression varies by stage: there is Level II evidence of antidepressant effects similar in magnitude to antidepressant medications in depressed perimenopausal women, with or without hot flashes, while it is ineffective for depressive disorders in postmenopausal women — which the panel calls a possible window of opportunity during the perimenopause. The same section states the evidence is not sufficient to recommend estrogen-based therapies for preventing depression in women without symptoms. Level II means limited or inconsistent evidence, and it is reported here as that.

For vaginal dryness, discomfort and urinary symptoms — genitourinary syndrome of menopause — the 2022 statement recommends low-dose vaginal estrogen or other local therapies when over-the-counter products haven't worked, in women who don't otherwise need systemic hormone therapy. That is a separate decision from whole-body treatment, and it gets lost in the broader hormone debate.

Non-hormonal prescription options

If hormone therapy is contraindicated — the 2023 statement names estrogen-dependent cancers and cardiovascular disease as examples — or you prefer not to take it, the alternatives are better evidenced than their reputation suggests. Here is that statement's full verdict for treating vasomotor symptoms, grades intact.

Source: The Menopause Society 2023 nonhormone therapy position statement, Menopause 30(6):573-590. Every verdict here refers to treating vasomotor symptoms — see the lifestyle section below, which matters more than the table does.

The line most readers will not expect is at the top. Cognitive behavioural therapy and clinical hypnosis sit at Level I — the same grade as the prescription drugs, and higher than several of them. These are not a soft option; on this scale they are among the best-evidenced non-hormonal approaches that exist. In the trials underpinning the CBT recommendation, 65% to 78% of women across studies reached a clinically significant threshold for improvement in how much their symptoms bothered them, maintained at 26 weeks.

One number explains a lot: trials of non-hormonal treatments for hot flashes carry a placebo improvement rate of 20% to 66%. That range is why individual testimonials, however sincere, are weak evidence here.

The two newest drugs

Two drugs here were approved recently enough that most guidance hasn't caught up, and one carries a safety update post-dating the guideline that recommends it.

Fezolinetant (Veozah) was FDA-approved in May 2023 as a neurokinin 3 receptor antagonist for moderate to severe vasomotor symptoms due to menopause, and the 2023 position statement gives it a Level I recommendation. On 16 December 2024, the FDA added a boxed warning — its most prominent warning — for the known risk of rare but serious liver injury (FDA Drug Safety Communication). That sequence matters: the Level I recommendation was published before the warning existed, so any page citing one without the other is out of date.

The specifics are checkable. The FDA acted after a post-marketing case in which a patient developed fatigue, nausea, itching, yellowing of the eyes and skin, light-coloured stools and dark urine within 40 days of starting the drug; symptoms and blood values gradually returned to normal after it was stopped. In the three trials behind approval, ALT and/or AST elevations above three times the upper limit of normal occurred in 2.3% of women taking fezolinetant against 0.9% on placebo (prescribing information via DailyMed). The label requires liver blood tests before starting, monthly for three months, then at six and nine months. None of this makes fezolinetant unreasonable — it remains recommended at Level I — but it is a drug with a monitoring schedule attached, and that belongs in the decision.

Elinzanetant (Lynkuet) was FDA-approved on 24 October 2025 for moderate to severe vasomotor symptoms due to menopause (FDA Drug Trials Snapshot); its label describes it as a neurokinin 1 and neurokinin 3 receptor antagonist (prescribing information via DailyMed). It post-dates every position statement in circulation, including both cited here, so no guideline covers it yet and it carries no evidence level — an absence of grading, not a poor grade.

What was measured is worth stating precisely. Approval rested on three trials — OASIS-1, OASIS-2 and OASIS-3 — involving 1,423 participants. OASIS-1 and OASIS-2 assessed efficacy, with co-primary endpoints of mean change from baseline in the frequency and severity of moderate to severe vasomotor symptoms at weeks 4 and 12; the FDA records that each showed statistically significant reductions against placebo on both, at both timepoints. We are not quoting a percentage reduction, because we could not verify effect magnitudes from a primary source. The efficacy trials enrolled postmenopausal women with a mean age of 55, not perimenopausal women, and women aged 65 and over were excluded. Safety was assessed in OASIS-3 over 52 weeks — real, but a year and no more; beyond that there is no long-term outcome data.

One point lands harder for perimenopausal readers than postmenopausal ones, because pregnancy is still possible: the label contraindicates elinzanetant in pregnancy, carries a warning for risk of pregnancy loss, and directs prescribers to exclude pregnancy before starting it. Its other warnings cover CNS depressant effects and daytime impairment, hepatic transaminase elevations, and — added in August 2026 — risk of seizure.

What lifestyle changes actually do

The honest version of this is easy to garble. The 2023 statement does not recommend exercise, yoga, mindfulness-based interventions, relaxation, cooling techniques, avoiding triggers or dietary modification as treatments for hot flashes and night sweats — and that qualification is not a footnote, it is the entire meaning of the verdict. The statement makes the distinction itself: "Although there are other health benefits associated with exercise or yoga, the evidence of those interventions for the treatment of VMS is sparse," and, in its key points, "A healthy diet is important for health promotion and chronic disease prevention; however, there is limited evidence to support dietary modifications as a tool for improving VMS."

So: exercise is not pointless in perimenopause. It is not a reliable way to reduce hot flash frequency. Those are different sentences, and only the second one is what the guideline says. Movement and nutrition still matter during this transition for bone, cardiovascular health, mood, sleep and muscle — and the muscle point is measurable. SWAN's body-composition analysis of 1,246 women found that lean mass rises by 0.2% per year before the transition and falls by 0.2% per year during it, while fat mass gain roughly doubles from 1.0% to 1.7% per year, even though total body weight continues on an unaltered trajectory (Greendale et al., 2019). A body recomposing while the scale stays flat is an argument for resistance training and adequate protein, not against them — the subject of perimenopause weight gain.

And one lifestyle intervention is affirmatively recommended for hot flashes in the very same document: weight loss, at Levels II-III. The statement's reasoning is specific to this stage — adiposity acts as a risk factor for vasomotor symptoms earlier in the transition, during perimenopause and early postmenopause, but not later, and weight loss may have greater effects on symptoms when women are earlier in the transition. If you are reading this while still having periods, that is the window the evidence describes.

Two related pages will go deeper: eating during perimenopause, and vitamins and supplements.

What the evidence doesn't support

For treating hot flashes and night sweats, supplements and herbal remedies are not recommended at Levels I-II — and the underlying trial data is more specific than a verdict.

Black cohosh, the most-purchased menopause botanical, was assessed in a 2012 Cochrane review of 16 randomised trials in 2,027 peri- or postmenopausal women over a mean of 23 weeks. There was no significant difference from placebo in vasomotor symptom frequency, and safety data were inconclusive. Separately, the US Pharmacopeial Convention's Dietary Supplements-Botanicals Expert Committee reviewed 30 reports possibly related to black cohosh and directed products to carry a warning to discontinue use and consult a practitioner in case of a liver disorder or symptoms of liver trouble.

Evening primrose oil produced the result that should be quoted more often. In the single trial, 56 women took either the oil or placebo for six months; vasomotor symptoms fell by 1.0 per day on the oil and by 2.6 per day on placebo. The placebo did better.

Again — a verdict about hot flashes and night sweats, not about nutrients generally. Calcium and vitamin D for bone, or correcting a genuine dietary shortfall, are a different question with a different evidence base. For a herb with menopause-specific trial data of its own, see ashwagandha for menopause.

How to decide, and what to ask

There is no flowchart here; any page offering one is overstepping. The decision turns on symptom severity, your personal and family medical history, how far into the transition you are, and what you actually want — which is why it belongs in an appointment rather than a search result. This page can at least make that appointment more productive.

Five questions worth writing down:

• Given my history, am I a candidate for hormone therapy — and if not, why not? Contraindications are individual, and "why not" is more useful than "no".
• Do I still need contraception, and does that change which option makes sense? Pregnancy remains possible throughout the transition, and this is the question most likely to go unasked.
• Which non-hormonal options would you consider for me, and at what evidence level? The grades above are public; a clinician can say which apply to you.
• When do we reassess, and what would tell us it isn't working? The 2022 statement calls for periodic reassessment, not an open-ended prescription.
• Does any option I'm considering require monitoring? Fezolinetant's liver blood testing schedule is the clearest example.

Two things help before you go. Where you are in the transition shapes the treat-or-wait calculation — see how long perimenopause and its symptoms last — and a hormone test usually isn't how the diagnosis is made, so a record of your cycle lengths and worst symptoms beats a blood result. If the terms are unclear, start with what perimenopause actually is and the full symptom picture.

Frequently asked questions about perimenopause treatment (FAQ)

What is the best treatment for perimenopause symptoms? For hot flashes and night sweats, hormone therapy is the most effective treatment available. The Menopause Society's 2022 position statement found the benefit-risk ratio favourable for women under 60 or within 10 years of menopause onset without contraindications, and less favourable when therapy starts more than 10 years out or after age 60, because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia. Whether it suits you is a clinical decision based on your history.

What can I take for hot flashes if I can't take hormones? The Menopause Society's 2023 nonhormone position statement gives Level I evidence — its highest grade — to SSRIs and SNRIs, gabapentin, fezolinetant, cognitive behavioural therapy and clinical hypnosis, and recommends oxybutynin at Levels I-II. Fezolinetant carries an FDA boxed warning for rare but serious liver injury, added on 16 December 2024, and requires liver blood testing before and during treatment. These are clinical decisions to make with a healthcare provider.

Is hormone therapy safe during perimenopause? Safety depends on your individual history, so no article can answer this for you. The Menopause Society's 2022 position statement concluded that for women under 60 or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favourable for treating bothersome hot flashes and night sweats and for preventing bone loss. It adds that risks vary by type, dose, duration, route and timing, and that treatment should be individualised with periodic reassessment.

Do supplements help perimenopause symptoms? For hot flashes and night sweats specifically, the Menopause Society's 2023 statement does not recommend supplements or herbal remedies (Levels I-II). A 2012 Cochrane review of 16 randomised trials in 2,027 women found no significant difference between black cohosh and placebo, and in the single evening primrose oil trial, placebo outperformed the supplement. That verdict covers vasomotor symptoms only — it does not address nutrients taken for bone health or to correct a genuine dietary shortfall.

Do I still need contraception during perimenopause? Yes. The Office on Women's Health states you can still get pregnant during perimenopause even if you miss your period for a month or a few months. The National Institute on Aging advises continuing birth control for at least a full 12 months after the last period if you don't want to conceive, because menopause can only be confirmed a year afterwards.

Medical disclaimer: This article is for informational purposes only. Always consult a qualified healthcare provider before making changes to your health routine.

Sources

1. The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause 2023;30(6):573-590 — Clinical position statement (PDF). https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
2. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29(7):767-794 — Clinical position statement (PDF). https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
3. US Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Boxed Warning update 16 December 2024 — Federal regulator drug safety communication. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
4. DailyMed, US National Library of Medicine. VEOZAH (fezolinetant) tablet, film coated — full prescribing information, Boxed Warning and Warnings and Precautions 5.1 — Official drug label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cae9f798-24f9-4580-a4fc-e6c710cbda3c
5. US Food and Drug Administration. Drug Trials Snapshots: LYNKUET (elinzanetant), approval date 24 October 2025 — Federal regulator trial summary. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-lynkuet
6. DailyMed, US National Library of Medicine. LYNKUET (elinzanetant) capsules — full prescribing information, including Contraindications and Warnings and Precautions — Official drug label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f42884ff-7dff-419c-8a0c-affe2ed73818
7. Cleveland Clinic. Perimenopause — Hospital patient information. https://my.clevelandclinic.org/health/diseases/21608-perimenopause
8. Office on Women's Health, US Department of Health and Human Services. Menopause basics — Government health information. https://womenshealth.gov/menopause/menopause-basics
9. National Institute on Aging (NIH). What Is Menopause? — Government health information. https://www.nia.nih.gov/health/menopause/what-menopause
10. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight 2019;4(5):e124865 — Peer-reviewed longitudinal cohort analysis (SWAN). https://insight.jci.org/articles/view/124865

All sources accessed 5 August 2026.

Claire Whitfield

Women's Health Specialist

A women's health specialist who reads the position statement itself, then checks what the regulator published after it.

View profileView Xing profile